We found that TMBIM1 interacts with Rab9a, localizing within lysosomes, which promotes the degradation of TGFBR1 and inhibits the TGF-β signaling pathway, thereby reducing CS and preventing HCC. Here, RAB9A is linked to hepatocellular carcinoma.